Paracrine effects of FGF23 on the heart

Frontiers in Endocrinology

Volumn 9, Issue MAY, 2018, Pages

  Leifheit Nestler, Maren ^a   Haffner, Dieter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Autocrine; Cardiac fibrosis; Cardiac remodeling; Endothelial dysfunction; Fibroblast growth factor 23; Left ventricular hypertrophy; Paracrine

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSINOGEN; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 16; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STAT PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ACUTE HEART FAILURE; BINDING AFFINITY; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART; HEART FAILURE; HEART FIBROBLAST; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL REPLACEMENT THERAPY; REVIEW; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING;

EID: 85047566910     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00278     Document Type: Review

References (112)

1. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet (2004) 20:563-9. doi: 10.1016/j.tig.2004.08.007
2. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2011) 149:121-30. doi: 10.1093/jb/mvq121
3. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 4:215-66. doi: 10.1002/wdev.176
4. Brewer JR, Mazot P, Soriano P. Genetic insights into the mechanisms of Fgf signaling. Genes Dev (2016) 30:751-71. doi: 10.1101/gad.277137.115
5. Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol (2016) 4:110. doi: 10.3389/fcell.2016.00110
6. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell (1994) 79:1015-24. doi: 10.1016/0092-8674(94)90032-9
7. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev (2005) 16:107-37. doi: 10.1016/j.cytogfr.2005.01.008
8. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 281:6120-3. doi: 10.1074/jbc.C500457200
9. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 444:770-4. doi: 10.1038/nature05315
10. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 27:3417-28. doi: 10.1128/MCB.02249-06
11. Goldfarb M, Schoorlemmer J, Williams A, Diwakar S, Wang Q, Huang X, et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron (2007) 55:449-63. doi: 10.1016/j.neuron.2007.07.006
12. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 24:2050-64. doi: 10.1210/me.2010-0142
13. Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol (2013) 4:247. doi: 10.3389/fphys.2013.00247
14. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 281:15694-700. doi: 10.1074/jbc.M601252200
15. Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 14:166-80. doi: 10.1038/nrm3528
16. Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol (2015) 25:221-33. doi: 10.1016/j.tcb.2014.11.003
17. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2004) 19:429-35. doi: 10.1359/JBMR.0301264
18. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 390:45-51. doi: 10.1038/36285
19. Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A (2014) 111:5520-5. doi: 10.1073/pnas.1402218111
20. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol (2009) 297:F282-91. doi: 10.1152/ajprenal.90742.2008
21. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 117:4003-8. doi: 10.1172/JCI32409
22. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 8:276-86. doi: 10.1038/nrendo.2011.218
23. Andrukhova O, Slavic S, Odorfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J Bone Miner Res (2015) 30:1831-9. doi: 10.1002/jbmr.2527
24. Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, et al. FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin. Oncotarget (2016) 7:64649-64. doi: 10.18632/oncotarget.11623
25. Leifheit-Nestler M, Grosse Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant (2016) 31:1088-99. doi: 10.1093/ndt/gfv421
26. Leifheit-Nestler M, Grabner A, Hermann L, Richter B, Schmitz K, Fischer DC, et al. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Nephrol Dial Transplant (2017) 32:1493-503. doi: 10.1093/ndt/gfw454
27. Bienaime F, Ambolet A, Aussilhou B, Brazier F, Fouchard M, Viau A, et al. Hepatic production of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. J Clin Endocrinol Metab (2018). doi: 10.1210/jc.2018-00123
28. Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One (2013) 8:e70775. doi: 10.1371/journal.pone.0070775
29. Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int (2014) 85:1340-50. doi: 10.1038/ki.2013.526
30. Mace ML, Gravesen E, Nordholm A, Hofman-Bang J, Secher T, Olgaard K, et al. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int (2017) 92:165-78. doi: 10.1016/j.kint.2017.01.015
31. Smith ER, Tan SJ, Holt SG, Hewitson TD. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Sci Rep (2017) 7:3345. doi: 10.1038/s41598-017-02709-w
32. Sugiura H, Matsushita A, Futaya M, Teraoka A, Akiyama KI, Usui N, et al. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model. PLoS One (2018) 13:e0191706. doi: 10.1371/journal.pone.0191706
33. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med (2010) 363:1833-45. doi: 10.1056/NEJMra0902710
34. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 121:4393-408. doi: 10.1172/JCI46122
35. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 359:584-92. doi: 10.1056/NEJMoa0706130
36. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab (2013) 304:E863-73. doi: 10.1152/ajpendo.00596.2012
37. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab (2015) 22:1020-32. doi: 10.1016/j.cmet.2015.09.002
38. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 119:2545-52. doi: 10.1161/CIRCULATIONAHA.108.844506
39. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant (2010) 25:2679-85. doi: 10.1093/ndt/gfq089
40. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 78:679-85. doi: 10.1038/ki.2010.194
41. Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol (2012) 27:2129-36. doi: 10.1007/s00467-012-2224-7
42. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 83:1159-68. doi: 10.1038/ki.2013.3
43. Sarmento-Dias M, Santos-Araujo C, Poinhos R, Oliveira B, Silva IS, Silva LS, et al. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clin Nephrol (2016) 85:135-41. doi: 10.5414/CN108716
44. Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, De Borst MH, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol (2013) 8:1968-78. doi: 10.2215/CJN.01880213
45. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci (2009) 337:116-22. doi: 10.1097/MAJ.0b013e3181815498
46. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 25:3983-9. doi: 10.1093/ndt/gfq309
47. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 305:2432-9. doi: 10.1001/jama.2011.826
48. Kirkpantur A, Balci M, Gurbuz OA, Afsar B, Canbakan B, Akdemir R, et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant (2011) 26:1346-54. doi: 10.1093/ndt/gfq539
49. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 207:546-51. doi: 10.1016/j.atherosclerosis.2009.05.013
50. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 152:640-8. doi: 10.7326/0003-4819-152-10-201005180-00004
51. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J (2011) 32:2688-96. doi: 10.1093/eurheartj/ehr215
52. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2013) 83:160-6. doi: 10.1038/ki.2012.327
53. Isakova T, Houston J, Santacruz L, Schiavenato E, Somarriba G, Harmon WG, et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol (2013) 28:2035-42. doi: 10.1007/s00467-013-2515-7
54. Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, et al. Association between circulating fibroblast growth factor 23, alpha-klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One (2013) 8:e73184. doi: 10.1371/journal.pone.0073184
55. Agarwal I, Ide N, Ix JH, Kestenbaum B, Lanske B, Schiller NB, et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc (2014) 3:e000584. doi: 10.1161/JAHA.113.000584
56. Imazu M, Takahama H, Asanuma H, Funada A, Sugano Y, Ohara T, et al. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. Am J Physiol Heart Circ Physiol (2014) 307:H1504-11. doi: 10.1152/ajpheart.00331.2014
57. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the multi-ethnic study of atherosclerosis. Circ Heart Fail (2014) 7:409-17. doi: 10.1161/CIRCHEARTFAILURE.113.000952
58. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology (2014) 82:1700-6. doi: 10.1212/WNL.0000000000000410
59. Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, et al. Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure. JACC Heart Fail (2015) 3:829-39. doi: 10.1016/j.jchf.2015.05.012
60. Andersen IA, Huntley BK, Sandberg SS, Heublein DM, Burnett JC Jr. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant (2016) 31:767-72. doi: 10.1093/ndt/gfv398
61. Wright CB, Shah NH, Mendez AJ, Derosa JT, Yoshita M, Elkind MS, et al. Fibroblast growth factor 23 is associated with subclinical cerebrovascular damage: the Northern Manhattan Study. Stroke (2016) 47:923-8. doi: 10.1161/STROKEAHA.115.012379
62. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens (2012) 21:369-75. doi: 10.1097/MNH.0b013e32835422c4
63. Kovesdy CP, Quarles LD. The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract (2013) 123:194-201. doi: 10.1159/000353593
64. Erben RG. Update on FGF23 and klotho signaling. Mol Cell Endocrinol (2016) 432:56-65. doi: 10.1016/j.mce.2016.05.008
65. Grabner A, Faul C. The role of fibroblast growth factor 23 and klotho in uremic cardiomyopathy. Curr Opin Nephrol Hypertens (2016) 25:314-24. doi: 10.1097/MNH.0000000000000231
66. Kovesdy CP, Quarles LD. FGF23 from bench to bedside. Am J Physiol Renal Physiol (2016) 310:F1168-74. doi: 10.1152/ajprenal.00606.2015
67. Erben RG. Pleiotropic actions of FGF23. Toxicol Pathol (2017) 45:904-10. doi: 10.1177/0192623317737469
68. Faul C. Cardiac actions of fibroblast growth factor 23. Bone (2017) 100:69-79. doi: 10.1016/j.bone.2016.10.001
69. Haffner D, Leifheit-Nestler M. Extrarenal effects of FGF23. Pediatr Nephrol (2017) 32:753-65. doi: 10.1007/s00467-016-3505-3
70. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant (2012) 27:3072-81. doi: 10.1093/ndt/gfs259
71. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol (2014) 10:268-78. doi: 10.1038/nrneph.2014.49
72. Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N. Association between FGF23, alpha-klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. PLoS One (2016) 11:e0156860. doi: 10.1371/journal.pone.0156860
73. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 98:6500-5. doi: 10.1073/pnas.101545198
74. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 112:3958-68. doi: 10.1161/CIRCULATIONAHA.105.590091
75. Slavic S, Ford K, Modert M, Becirovic A, Handschuh S, Baierl A, et al. Genetic ablation of Fgf23 or klotho does not modulate experimental heart hypertrophy induced by pressure overload. Sci Rep (2017) 7:11298. doi: 10.1038/s41598-017-10140-4
76. Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol A, et al. Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun (2016) 470:384-90. doi: 10.1016/j.bbrc.2016.01.034
77. Kakkar R, Lee RT. Intramyocardial fibroblast myocyte communication. Circ Res (2010) 106:47-57. doi: 10.1161/CIRCRESAHA.109.207456
78. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest (1999) 104:709-19. doi: 10.1172/JCI7315
79. Jiang ZS, Jeyaraman M, Wen GB, Fandrich RR, Dixon IM, Cattini PA, et al. High-but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol (2007) 42:222-33. doi: 10.1016/j.yjmcc.2006.09.002
80. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, Hurley MM. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and klotho. J Biol Chem (2010) 285:2834-46. doi: 10.1074/jbc.M109.030577
81. Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res (2013) 28:35-45. doi: 10.1002/jbmr.1721
82. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 7:e44161. doi: 10.1371/journal.pone.0044161
83. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling. J Am Soc Nephrol (2013) 24:771-85. doi: 10.1681/ASN.2012080865
84. Smith ER, Holt SG, Hewitson TD. FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-beta autoinduction. Int J Biochem Cell Biol (2017) 92:63-78. doi: 10.1016/j.biocel.2017.09.009
85. Lam AP, Gottardi CJ. beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol (2011) 23:562-7. doi: 10.1097/BOR.0b013e32834b3309
86. Guo Y, Xiao L, Sun L, Liu F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res (2012) 61:337-46
87. Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, et al. FGF23 is induced by activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol Dial Transplant (2018). doi: 10.1093/ndt/gfy006
88. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis (2009) 205:385-90. doi: 10.1016/j.atherosclerosis.2009.01.001
89. Voigt M, Fischer DC, Rimpau M, Schareck W, Haffner D. Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology (2010) 56:775-88. doi: 10.1111/j.1365-2559.2010.03547.x
90. van Venrooij NA, Pereira RC, Tintut Y, Fishbein MC, Tumber N, Demer LL, et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant (2014) 29:1525-32. doi: 10.1093/ndt/gft523
91. Richter B, Haller J, Haffner D, Leifheit-Nestler M. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch (2016) 468:1621-35. doi: 10.1007/s00424-016-1858-x
92. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation (2015) 131:1019-30. doi: 10.1161/CIRCULATIONAHA.114.008788
93. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol (2012) 7:1155-62. doi: 10.2215/CJN.13281211
94. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 90:985-96. doi: 10.1016/j.kint.2016.05.019
95. Yan L, Bowman MA. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. Inflamm Cell Signal (2014) 1:e279. doi: 10.14800/ics.279
96. Dey G, Radhakrishnan A, Syed N, Thomas JK, Nadig A, Srikumar K, et al. Signaling network of oncostatin M pathway. J Cell Commun Signal (2013) 7:103-8. doi: 10.1007/s12079-012-0186-y
97. Kubin T, Poling J, Kostin S, Gajawada P, Hein S, Rees W, et al. Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell (2011) 9:420-32. doi: 10.1016/j.stem.2011.08.013
98. Schaefer LK, Wang S, Schaefer TS. Oncostatin M activates stat DNA binding and transcriptional activity in primary human fetal astrocytes: low-and high-passage cells have distinct patterns of stat activation. Cytokine (2000) 12:1647-55. doi: 10.1006/cyto.2000.0774
99. Van Wagoner NJ, Choi C, Repovic P, Benveniste EN. Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38. J Neurochem (2000) 75:563-75. doi: 10.1046/j.1471-4159.2000.0750563.x
100. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet (2008) 82:73-80. doi: 10.1016/j.ajhg.2007.09.002
101. Richter M, Polyakova V, Gajawada P, Pöling J, Warnecke H, Braun T, et al. Oncostatin M induces FGF23 expression in cardiomyocytes. J Clin Exp Cardiolog (2012) S9:003. doi: 10.4172/2155-9880.S9-003
102. Richter M, Lautze HJ, Walther T, Braun T, Kostin S, Kubin T. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J Heart Lung Transplant (2015) 34:1211-4. doi: 10.1016/j.healun.2015.06.007
103. Han X, Li L, Yang J, King G, Xiao Z, Quarles LD. Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett (2016) 590:53-67. doi: 10.1002/1873-3468.12040
104. Fajol A, Chen H, Umbach AT, Quarles LD, Lang F, Foller M. Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by beta-blocker treatment. FASEB J (2016) 30:994-1001. doi: 10.1096/fj.15-279943
105. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 122:2543-53. doi: 10.1172/JCI61405
106. Fukumoto S. Anti-fibroblast growth factor 23 antibody therapy. Curr Opin Nephrol Hypertens (2014) 23:346-51. doi: 10.1097/01.mnh.0000447012.98357.da
107. Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci (2016) 37:1081-96. doi: 10.1016/j.tips.2016.10.003
108. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'donnell TF, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol (2014) 63:2421-8. doi: 10.1016/j.jacc.2014.03.026
109. Ter Maaten JM, Voors AA, Damman K, Van Der Meer P, Anker SD, Cleland JG, et al. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol (2018) 253:84-90. doi: 10.1016/j.ijcard.2017.10.010
110. Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, et al. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade. Am J Kidney Dis (2015) 65:259-66. doi: 10.1053/j.ajkd.2014.07.022
111. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens (2014) 23:411-9. doi: 10.1097/01.mnh.0000447020.74593.6f
112. Shroff R, Aitkenhead H, Costa N, Trivelli A, Litwin M, Picca S, et al. Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol (2016) 27:314-22. doi: 10.1681/ASN.2014090947